-
The four departments announced the third batch of anti-cancer drugs and rare disease drugs subject to the value-added tax policy
Time of Update: 2023-01-05
The Ministry of Finance, the General Administration of Customs, the State Administration of Taxation, and the State Medical Products Administration announced in April 2018 that from May 1, 2018, general VAT taxpayers who produce, sell, wholesale, and retail anti-cancer drugs can choose to pay VAT at a rate of 3% according to the simplified method; For imported anti-cancer drugs, import value-added tax will be levied at a reduced rate of 3%.
-
The acceleration of new drug launches in China is bringing more choices for clinical treatment
Time of Update: 2022-11-11
On November 7, Jinxing Pharmaceutical announced that the Center for Drug Evaluation of the State Food and Drug Administration has accepted its application for the marketing of omecamtiv mecarbil, whic
-
Professor Yang Du of Science and collaborators published the development of non-opioid addiction-free analgesic drugs
Time of Update: 2022-10-13
The pain and opioid abuse pandemic has highlighted the need for new non-opioid treatments for pain. Many non-opioid receptors are involved in pain management (injury perception), but only a few of the
-
"Merro" or "Imine", how to choose carbapenems reasonably
Time of Update: 2022-06-06
With the continuous development of medicinal chemistry, panipenem, meropenem, ertapenem and other drugs have been added to the carbapenem family, providing more options for clinical diagnosis and treatment of bacterial infections .
-
FDA approves emergency use of second oral drug to treat COVID-19
Time of Update: 2022-02-24
S. Food and Drug Administration approved the first oral drug for emergency use in the treatment of new coronavirus infections on the 22nd .
-
The raw material drug Cetirizine Hydrochloride, a wholly-owned subsidiary of Warner Pharmaceuticals, passed the CDE approval
Time of Update: 2021-09-20
passed the CDE approval .
Cetirizine hydrochloride, the second-generation histamine H1 receptor antagonist (anti-allergic drug), is mainly used for respiratory, skin and eye allergic diseases, including perennial allergic diseases, such as allergic skin diseases, Look for measles, allergic rhinitis, itchy eyes, conjunctivitis and asthma .
-
Lost millions of dollars
Time of Update: 2021-09-05
CompilationFan DongdongA few days ago, US healthcare and health plan provider Kaiser Permanente has filed a lawsuit against drug maker Merck, claiming that the company’s "paid delay" plan caused it to lose millions of dollars .
-
Roche Huntington’s ASO Phase III clinical trial stopped
Time of Update: 2021-04-27
Tominersen is an anti-nucleic acid drug that binds to Huntington mRNA and degrades this mRNA through the RNA degradation system, thus reducing the expression of toxic proteins, which may change the course of the disease.
-
Biogen Alzheimer's monoclonal antibody aducanumab was criticized by the FDA committee
Time of Update: 2021-04-14
According to Bojian, the data of a group of patients who received a sufficiently high dose of drug treatment showed significant benefits in terms of cognition and function, including memory, orientation, and language, as well as benefits for activities of daily living.
-
Haisco's "Avanafil Tablets" will soon be approved for listing
Time of Update: 2021-03-21
Recently, the official website of the State Food and Drug Administration showed that Haisco’s application for the listing of avanafil tablets (acceptance numbers: CYHS1900563, CYHS1900564) submitted by registration classification 3 (domestic applicants imitated overseas listings but the original research was not listed domestically) has been At the "approval" stage, it is expected that the NMPA will approve the listing in the near future, and it will be the first imitation of this variety after listing.
-
FDA approves Vertex clinical test stem cell-derived fully differentiated islet cell therapy
Time of Update: 2021-03-12
Vertex plans to launch a phase 1/2 single-arm, open-label clinical trial in the first half of 2021, using VX-880 to treat patients with type 1 diabetes (T1D) with impaired and severe hypoglycemia.
-
Tiansli osteoporosis drug minoic acid tablets were approved for drug registration
Time of Update: 2021-01-31
Minoic acid tablets received clinical approval in May 2014, completed human pharmacodynamics trials in December 2015, completed validated clinical trials in January 2018, and completed human bioethic
-
State Drug Administration: the second batch of national key laboratories public list
Time of Update: 2021-01-30
: Tao Yamin Contact: 010-88331105 E-mail: kbskjc@nmpa.gov.cn Address: Beijing Xicheng Exhibition Road, North Luyuan 1 Building, State Drug Administration Postcode of the Division of Science, Technology and International Cooperation: Annex: Annex 100037: The second batch of key laboratories of the State Drug Administration made public the list of key laboratories of the Division of Science, Technology and International Cooperation by 22 January 2021 Annex: The second batch of key laboratories passed the list of judges
-
The development of the psychopic drug ketamine, which has been on the market for decades, is still on the way
Time of Update: 2021-01-09
Among the many drugs on the market, it is worth mentioning the variety, when (Ace) ketamine, after decades of clinical use, finally in 2019 through the improvement of dosage forms and officially turned to the field of antidepressants, and become the world's only fast-acting antidepressants, causing widespread concern in the industry!
-
Yingpai Pharmaceuticals Wee1 inhibitors are declared clinical in China
Time of Update: 2021-01-06
According to the latest announcement from the Drug Review Center (CDE) of the State Drug Administration of China, Yingpai Pharmaceuticals submitted an application for a clinical trial in the study of Wee1 inhibitor IMP7068, which was accepted on December 7.
